Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has undertaken an exercise to fix and revise ceiling prices of 45 new formulations, including commonly used antibiotic rifampicin, oral paracetamol and asthmatic medicine salbutamol.
The authority said it has notified ceiling prices of nine scheduled formulations, while revising the ceiling price of 36 scheduled formulations which are under price control.
Moreover, NPPA said it has fixed the retail prices of 11 formulations under DPCO, 2013.
These include diabetes drugs Teneligliptin and Metformin HCl Tablet manufactured by Glenmark Pharmaceuticals and Macleods Pharmaceuticals Ltd among others.
The retail price of diclofenac sodium and paracetamol tablet used in treatment of soft tissue injuries.
With this, a total of 540 formulations have been brought under price control since March 10, 2016, it said in a tweet.
The government had notified DPCO, 2013, which covers 680 formulations, with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs.
Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs.
Disclaimer: No Business Standard Journalist was involved in creation of this content
